Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Abbott Laboratories Rises to Record High on Hepatitis Drug Study


A company study shows more than 90% cure rates with an experimental pill, solidifying Abbott's place in a crowded field of drug developers.

Abbott Laboratories (ABT) is making a case that it's a serious contender to develop a better drug to treat the liver-destroying virus hepatitis C.

In a pair of small studies, Abbott showed that its experimental pills taken with other drugs can cure more than 90% of patients with the virus. In one trial closely watched by investors, dubbed Co-Pilot, two groups of patients showed 95% and 93% cure rates when given the Abbott drugs. Abbott said the study also showed a 47% cure rate for another group of people who couldn't be treated by medicines already approved for sale.

"The Abbott data is clearly impressive from an efficacy standpoint," ISI Group analyst Mark Schoenebaum says. But he notes that more data is needed to get a clear impression of the treatment.

Abbott is in the second of three phases of study usually needed to win US approval for drugs. The study results will be presented at a major medical conference focused on liver diseases, held in Spain later this month.

The news was good for Abbott and the company's shares rose 1% to $61.54 in midday trading. (The stock was above $62 in morning trading.)

Abbott is in a race with a crowd of rivals, including Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Merck (MRK), Vertex Pharmaceuticals (VRTX), Indenix Pharmaceuticals (IDIX), and Roche (RHHBY.PK).

Shares of some of those companies dropped today. Gilead fell 2% to $47.26 in midday trading, while Vertex dropped 1%, and Bristol-Myers slid less than 1%. Idenix fell 12% to $9.

The goal for the next generation of hepatitis C drugs is to develop an all-oral drug regimen that doesn't require an injection of the drug interferon, which can cause nasty side effects.

Demand for hepatitis treatments is expected to rise as many people infected years ago may have the virus and not realize it. As many as 170 million people worldwide have chronic infections and more than 350,000 people die from the virus each year, according to estimates by the World Health Organization. More than 3 million people in the US have chronic infections, according to the Centers for Disease Control and Prevention.

The payoff for the company that successfully brings a new treatment to the market is potentially billions of dollars. Some of Abbott's competitors spent big bucks to try to get ahead in the race. Most recently, Bristol-Myers acquired drug developer Inhibitex following Gilead's whopper $11 billion deal for Pharmasset. (See Bristol-Myers Enters Hepatitis Drug Race with $2.5 billion takeover of Inhibitex)

Abbott is actually in the midst of spinning off its drug business into a new company that will be called AbbVie. The process is supposed to be complete by the end of the year.

More study data from Gilead and Bristol-Myers will be coming out of the conference in Spain, which begins April 18.

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos